SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 5th, 2021 • Rapid Therapeutic Science Laboratories, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 1, 2021, between Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
COMMON STOCK PURCHASE WARRANT RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.Securities Agreement • August 5th, 2021 • Rapid Therapeutic Science Laboratories, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on August 3, 2026(the “Termination Date”) but not thereafter, to subscribe for and purchase from Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (the “Company”), up to 4,852,940 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.Placement Agent's Warrant • August 5th, 2021 • Rapid Therapeutic Science Laboratories, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Maxim Group LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on August 4, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (the “Company”), up to 242,647 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
LEAK-OUT AGREEMENTLeak-Out Agreement • August 5th, 2021 • Rapid Therapeutic Science Laboratories, Inc. • Pharmaceutical preparations
This agreement (the “Leak-Out Agreement”) is being delivered to you in connection with an understanding by and among Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (the “Company”), and the person or persons named on the signature pages hereto (collectively, the “Holder”).
ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE DUE MAY 1, 2022Securities Agreement • August 5th, 2021 • Rapid Therapeutic Science Laboratories, Inc. • Pharmaceutical preparations • New York
THIS ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued Original Issue Discount Convertible Debentures of Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (the “Company”), having its principal place of business at 15800 Dooley Road, Suite 200, Addison, TX 75001, designated as its Original Issue Discount Convertible Debenture due May 1, 2022 (this debenture, the “Debenture” and, collectively with the other debentures of such series, the “Debentures”).
